Tracking cancer drug performance in everyday patients
NCT ID NCT04945330
Summary
This study collects real-world information about larotrectinib, a targeted cancer drug already available by prescription. Researchers want to understand the safety and effectiveness of this treatment in adults and children with advanced or recurrent TRK fusion cancer during routine medical care. The study gathers data from medical records and doctor visits without requiring additional tests or appointments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT SOLID TUMOR HARBORING AN NTRK GENE FUSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan
Conditions
Explore the condition pages connected to this study.